Pregnolia is a Zurich-based medical device company focused on obstetrics, specifically the early prediction of preterm birth through the measurement of cervical stiffness. Its handheld diagnostic device provides clinicians with a quantitative biomarker that early studies indicate is more reliable than current standard methods. Three recent peer-reviewed publications in leading journals have reinforced the validity of cervical stiffness as a predictor, bolstering the company’s scientific foundation. Pregnolia plans to use its technology to make cervical stiffness assessment part of routine prenatal care and is already working on an FDA approval strategy for the U.S. market. The company recently attracted competitive European Innovation Council (EIC) support, underscoring the perceived impact of its solution. Financially, Pregnolia has raised CHF 3.4 million (~$4.4 million) in its latest round, following a CHF 2.2 million round in 2023 that funded multi-country clinical studies. The new capital will fund further clinical validation and steps toward commercialization.

Total raised

$15M

Funding rounds

5

Latest round

Equity

Latest activity

Mar 2026